PG 22000Alternative Names: PG 2-2000
Latest Information Update: 10 Jan 2008
At a glance
- Originator Pharmagenesis
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Haematological disorders
Most Recent Events
- 02 Nov 2005 No development reported - Preclinical for Haematological disorders in USA (unspecified route)
- 08 Nov 2001 Preclinical development for Haematological disorders in USA (unspecified route)